Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics is a Waltham biopharmaceutical company developing antibody treatments for blood disorders. It last closed at $22.56 on Nov 17, up 0.29% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From DMRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on DMRA in the past 90 days. The average target is $59.00, with a high of $59.00 and a low of $59.00, compared with the last close of $22.56.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | Guggenheim | Maintained | Buy | $59 |
| Sep 25 | Guggenheim | Maintained | Buy | $60 |
| Jul 30 | Wedbush | Target raised | Buy | $35 → $40 |
| Jul 27 | Jefferies | Initiated | Buy | $50 |
| Jun 12 | Wedbush | Reiterated | Buy | $35 |
Technical Analysis
The stock is 1% above its 20 day and 3% above its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot at $22.40, and the nearest resistance the swing high (Oct 21) at $22.68.
| RSI (14) | 52.06 | Middle of its range | Neutral |
| MACD | 0.25 | Above its signal line | Bullish |
| Stochastic | 38.1 | Middle of its range | Neutral |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -58.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 13.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +2.2% | Change over 10 sessions | Bullish |
| ATR (14) | $1.69 | Typical daily range, 7.5% of price |
| RSI (14) | 47.08 | Middle of its range | Neutral |
| MACD | -0.99 | Below its signal line | Bearish |
| Stochastic | 31.9 | Middle of its range | Neutral |
| ADX (14) | 16.9 | No clear trend | |
| Williams %R | -68.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -52.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −19.7% | Change over 10 sessions | Bearish |
| ATR (14) | $4.10 | Typical daily range, 18.2% of price |
What happened before
See how DMRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DMRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in DMRA in the last 90 days.
DMRA Institutional Ownership
Full report →- ▲107 buying vs 2 selling
- ▲Held by funds +95.8 pts
- ▲Funds holding +108
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 111 | 3 | +3600.0% |
| In funds' top 10 | 4 | 0 | – |
| Held by funds | 95.9% | 0.1% | +95.8 pts |
| New / increased | 107 / 0 | 3 / 0 | +3466.7% |
| Reduced / sold out | 2 / 0 | 0 / 0 | – |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMRA is in one of them and how their past DMRA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DMRA in an article yet. Here's the latest on the wider market.
About Damora Therapeutics
Damora Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts, that develops treatments for blood disorders. Its lead candidate, DMR-001, is an antibody designed to target mutant calreticulin, a protein that drives essential thrombocythemia and myelofibrosis, two myeloproliferative neoplasms that affect the bone marrow. The company is also developing two related candidates for the same group of disorders. Its intended patients are people living with these conditions, and none of its candidates are on the market yet.
- Headquarters
- Waltham, MA

